Assessing glycemic and weight-lowering potential of oral semaglutide in type 2 diabetes compared to other GLP-1 receptor agonists in Indian context

被引：0
|
作者：
Singh, Awadhesh Kumar [1 ,2 ,3 ]
Chawla, Rajeev [4 ]
机构：
[1] GD Hosp & Diabet Inst, Kolkata 700013, West Bengal, India
[2] Horizon Multispecial Hosp, Kolkata, West Bengal, India
[3] Sun Valley Hosp & Diabet Res Ctr, Gauhati, Assam, India
[4] North Delhi Diabet Ctr, New Delhi, India
来源：
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES | 2024年 / 44卷 / 02期
关键词：
ONCE-WEEKLY SEMAGLUTIDE; OPEN-LABEL; PHASE; 3A; CARDIOVASCULAR OUTCOMES; JAPANESE PATIENTS; ADD-ON; EFFICACY; SAFETY; DULAGLUTIDE; METFORMIN;
D O I：
10.1007/s13410-024-01337-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 215
页数：5
相关论文
共 50 条
  • [41] A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Kayaniyil, Sheena
    Lozano-Ortega, Greta
    Bennett, Heather A.
    Johnsson, Kristina
    Shaunik, Alka
    Grandy, Susan
    Kartman, Bernt
    DIABETES THERAPY, 2016, 7 (01) : 27 - 43
  • [42] The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists
    Serowik, Thomas C.
    Pantalone, Kevin M.
    JOURNAL OF OSTEOPATHIC MEDICINE, 2024, 124 (03): : 127 - 135
  • [43] Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach
    Overgaard, Rune V.
    Lindberg, Soren O.
    Thielke, Desiree
    DIABETES OBESITY & METABOLISM, 2019, 21 (01) : 43 - 51
  • [44] GLP-1 Receptor Agonists Critical Review: Revisiting Its Positioning for Type 2 Diabetes Mellitus in Routine Clinical Practice in India
    Rajput, Rajesh
    Sinha, Binayak
    Lodha, Sailesh
    Deb, Prasun
    Das, Sambit
    Agarwal, Sanjay
    Das, A. K.
    Thomas, Nihal
    CLINICAL DIABETOLOGY, 2022, 11 (04): : 269 - 293
  • [45] The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
    Russell-Jones, D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) : 1402 - 1414
  • [46] Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy
    Wright, Jr Eugene E.
    Aroda, Vanita R.
    POSTGRADUATE MEDICINE, 2020, 132 : 26 - 36
  • [47] The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
    Aroda, Vanita R.
    Ratner, Robert
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (06) : 528 - 542
  • [48] A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
    Montanya, Eduard
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1451 - 1467
  • [49] The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
    von Scholten, Bernt Johan
    Kreiner, Frederik Flindt
    Rasmussen, Soren
    Rossing, Peter
    Idorn, Thomas
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [50] Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes
    Sassenrath, Kimberly
    Phillips, Beth Bryles
    Stone, Rebecca H.
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (06) : 979 - 990
12345